Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Beecham Group plc, 980 Great West Road, Brentford, Middlesex TW8 9GS Trading as: GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Bactroban 2% Nasal Ointment.
| Pharmaceutical Form |
|---|
|
White soft paraffin based nasal ointment containing a glycerin ester. Off-white smooth ointment. |
Each gram of nasal ointment contains mupirocin calcium equivalent to 20 mg mupirocin (2% w/w mupirocin free acid).
| Active Ingredient | Description | |
|---|---|---|
| Mupirocin |
Mupirocin is a novel antibiotic produced through fermentation by Pseudomonas fluorescens. Mupirocin inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally. |
| List of Excipients |
|---|
|
White soft paraffin |
Lacquered aluminium tube fitted with a nozzle and screw cap containing 3 g ointment.
Beecham Group plc, 980 Great West Road, Brentford, Middlesex TW8 9GS
Trading as: GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
PL 00038/0347
Date of first authorisation: 7 March 1988
Date of last renewal: 21 May 2008
| Drug | Countries | |
|---|---|---|
| BACTROBAN | Austria, Australia, Brazil, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Malta, Mexico, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
